Physician profile
Paul D Carter
NPI 1639205792
$10,234.97
in general payments reported to CMS, 2019-2025
45 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,322 · 2022: $2,174 · 2023: $2,291 · 2024: $1,911 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,738.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,962.27 | 2021-2025 | |
| Novo Nordisk INC | $1,043.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $926.89 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $857.83 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $471.24 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $471.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.26 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $354.19 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $336.00 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.97 | 2021-2024 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $307.56 | 2021-2025 | |
| Amgen INC. | $289.02 | 2021-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $247.34 | 2022 | |
| Abbott Laboratories | $186.04 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $159.45 | 2021-2025 | Veozah, Myrbetriq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.